Expression of p57 marker in differential diagnosis of complete and partial mole – correlation with DNA analysis
Authors:
Z. Čierna 1; M. Palkovič 1; Ľ. Danihel ml. 1; Ľudovít Danihel 1; Vanda Repiská 2; J. Vojtaššák 2; M. Korbeľ 3
Authors‘ workplace:
Ústav patologickej anatómie LF UK a UNB, Bratislava
1; Ústav lekárskej biológie, genetiky a klinickej genetiky LF UK a UNB, Bratislava
2; I. gynekologicko-pôrodnícka klinika LF UK a UNB, Bratislava
3
Published in:
Čes.-slov. Patol., 48, 2012, No. 4, p. 218-221
Category:
Original Articles
Overview
Nowadays valid classification of gestational trophoblastic disease, according to the World Health Organisation from the year 2003, divides gestational trophoblastic disease into three groups – molar pregnancies, non-neoplastic non-molar changes of trophoblast and tumours of trophoblast. To the molar pregnancies belong complete, partial, invasive and metastatic hydatidiform mole. In the differential diagnosis it is important to distinguish the complete hydatidiform mole from other forms of gestational trophoblastic disease, because there is an increased risk of malignant transformation of trophoblast cells in complete hydatidiform mole. 10 cases of genetically confirmed diploid complete mole and 10 cases of genetically confirmed triploid partial mole were included into our retrospective study. All cases were examined microscopically in the basic haematoxillin and eosin staining and immunohistochemically with the use of antibodies against human choriogonadotropin hormone, placental alkaline phosfatase and protein p57. Villous cytotrophoblast, stromal villous cells, extravillous trophoblast and decidual cells were p57 positive in all cases of partial hydatidiform mole. All 10 cases of complete hydatidiform mole were p57 negative in stromal villous cells and villous cytotrophoblast. P57 protein is a marker distinguishing complete hydatidiform moles from partial moles.
Keywords:
gestational trophoblastic disease – complete hydatidiform mole – partial hydatidiform mole – p57 protein – immunohistochemistry
Sources
1. Genest DR, Berkowitz RS, Fisher RA, Newlands ES, Fehr M. Gestational trophoblastic disease. In: Tavassoli, FA, Deville, P, eds. WHO classification of Tumors, Pathology and Genetics, Tumours of the Brest and Female Genital Organs. Tumours of the uterine corpus. Lyon: IARC Press; 2003: 217–258.
2. Korbeľ M, Nižňanská Z, Redecha M, et al. Kompletná a parciálna mola hydatidóza – etiopatogenéza, diagnostika, liečba a dispenzarizácia. Gynekol prax 2007; 5 (2): 106–112.
3. Shih IeM. Gestational trophoblastic lesions. In: Nucci MR, Oliva E, eds. Gynecologic pathology. London: Churchill Livingstone; 2009: 645–665.
4. Repiská V, Vojtaššák J, Korbeľ M, et al. DNA analýza gestačnej trofoblastovej choroby. Ces Gynek 2003; 68 (6): 442–448.
5. Zavadil M, Feyereisl j, Hejda V, Krofta L, Šafář P. Histologická diferenciální diagnostika hydatidóznych mol a hydropických abortů. Cesk Patol 2009; 45(1): 3–8.
6. Clement PB, Young RH. Atlas of gynecologic surgical pathology. W.B. Saunders Company; 2000: 2211–2228.
7. Shih IeM, Mazur MT, Kurman RJ. Gestational trophoblastic tumors and related tumor-like lesions. In: Kurman RJ, eds. Blaustein’s Pathology of the Female Genital Tract (6th ed). New York: Springer – Verlag; 2011: 1075–1135.
8. Fox H, Sebire NJ. Gestational trophoblastic disease. In: Pathology of the Placenta (3th ed). Saunders Elsevier; 2007: 431–472.
9. Danihel Ľ, Černá A, Šišovský V, Palkovič M. Súčasná klasifikácia a morfologická charakteristika nádorov trofoblastu. Onkológia (Bratisl.) 2008; 3(4): 230–232.
10. Lage J. Gestational trophoblastic diseases. In: Robboy, SJ, Anderson, MC, Russel, P, eds. Pathology of the female reproductive tract. London: Churchill Livingstone; 2002: 759–781.
11. Kaščák P, Lintner R. Choriokarcinóm. Gynekol prax 2005; 3(2): 123–125.
12. McCluggage WG. Immunohistochemistry in the differential diagnosis of female genital tract pathology. In: Nucci MR, Oliva E, eds. Gynecologic pathology. London: Churchill Livingstone; 2009: 667–694.
13. Sharifi N, Sadeghian MH, Ayatollahi H, Daluei MK, Rezaea AR, Keramati MR. Validity of p57 immunohistochemical marker in differential diagnosis of molar pregnancy. J Turkish-German Gynecol Assoc 2009; 10: 39–42.
14. Danihel Ľ, Porubský J, Zaviačič T, Vojtaššák J, Breitenecker G. Trofoblastická choroba. I. Využitie imunohistochémie pri diagnostike kompletnej hydatidóznej moly. Cesk Patol 1994; 30(3): 76–79.
15. Danihel Ľ, Porubský J, Vojtaššák J, Breitenecker G. Trofoblastická choroba. II. Imunohistochemické a cytogenetické parametre parciálnej hydatidóznej moly. Cesk Patol 1994; 30(3): 80–84.
16. Guo H, Tian T, Nan K, Wang W. p57: A multifunctional protein in cancer (Review). Int J Oncol 2010; 36: 1321–1329.
17. Fisher RA, Hodges MD, Rees HC, et al. The maternally transcribed gene p57KIP2 (CDNK1C) is abnormally expressed in both androgenetic and biparental complete hydatidiform moles. Hum Molec Genet 2002; 26(11): 3267–3272.
18. Chilosi M, Piazzola E, Lestani M, et al. Differential expression of p57kip2, a maternally imprinted cdk inhibitor, in normal human placenta and gestational trophoblastic disease. Lab Invest 1998; 78(3): 269–276.
19. Genest DR, Dorfman DM, Castrillon DH. Ploidy and imprinting in hydatidiform moles. Complementary use of flow cytometry and immunohistochemistry of the imprinted gene product p57KIP2 to assist molar classification. J Reprod Med 2002; 47(5): 342–346.
20. Sebire NJ, Rees HC, Peston D, Seckl MJ, Newlands ES, Fisher RA. p57(KIP2) immunohistochemical staining of gestational trophoblastic tumours does not identify the type of the causative pregnancy. Histopathology 2004; 45(2): 135–141.
21. Castrillon DH, Sun D, Weremowicz S, Fisher RA, Crum CP, Genest DR. Discrimination of complete hydatidiform mole from its mimics by immunohistochemistry of the paternally imprinted gene product p57KIP2. Am J Surg Pathol 2001; 25(10): 1225–1230.
22. Crisp H, Burton JL, Stewart R, Wells M. Refining the diagnosis of hydatidiform mole: image ploidy analysis and p57KIP2 immunohistochemistry. Histopathology 2003; 43(4): 363–373.
23. Fukunaga M. Immunohistochemical characterization of p57(KIP2) expression in early hydatidiform moles. Hum Pathol 2002; 33(12): 1188–1192.
24. Fisher RA, Nucci MR, Harshwardhan MT, Weremowicz S, Genest DR, Castrillon DH. Complete hydatidiform mole retaining a chromosome 11 of maternal origin: molecular genetic analysis of a case. Modern Pathology 2004; 17: 1156–1160.
25. McConnell TG, Norris-Kirby A, Hagenkord JM, Ronnett BM, Murphy KM. Complete hydatidiform mole with retained maternal chromosomes 6 and 11. Am J Surg Pathol 2009; 33(9): 1409–1415.
26. DeScipio C, Haley L, Bejerl K, Pandit AP, Murphy KM, Ronnett BM. Diandric triploid hydatidiform mole with loss of maternal chromosome 11. Am J Surg Pathol 2011; 35(10): 1586–1591.
Labels
Anatomical pathology Forensic medical examiner ToxicologyArticle was published in
Czecho-Slovak Pathology
2012 Issue 4
Most read in this issue
- Histiocytic necrotizing lymphadenitis / Kikuchi-Fujimoto disease (HNL/K-F) and its differential diagnosis: analysis of 19 patients
- Pleomorphic adenoma of salivary glands: diagnostic pitfalls and mimickers of malignancy
- Pseudotumors of the central nervous system
- Expression of p57 marker in differential diagnosis of complete and partial mole – correlation with DNA analysis